Determination of Prevalence and Features of HRRm mCRPC (ADAM)

Plain-language summary

This observational study aimed to determine the prevalence and features of homologous recombination repair (HRR) gene mutations in patients with metastatic castration-resistant prostate cancer. Men aged 18 or older with histologically confirmed prostate cancer and documented metastatic castration-resistant disease were included. This study without an assigned phase has been carried out and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

AstraZeneca

Start date

10/23/2020

Estimated completion

9/30/2022

Countries

Russia

Related genes

Locations

• Barnaul, Russia
• Ufa, Russia
• Chelyabinsk, Russia
• Krasnoyarsk, Russia
• Saint Petersburg, Russia
• Nizhny Novgorod, Russia
• Omsk, Russia
• Vladivostok, Russia
• Yuzhno-Sakhalinsk, Russia
• Yekaterinburg, Russia
• Tyumen, Russia
• Yaroslavl, Russia
• Moscow, Russia
• Saint Petersburg, Russia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male 18 years age or older
* Provision of written informed consent
* Histologically confirmed diagnosis of prostate cancer
* Documented evidence of metastatic castration resistant prostate cancer (mCRPC)
* Patients who are on the first line therapy or already received one line of therapy due to mCRPC previously
* Availability of archival FFPE tissue from primary prostate tumor
* Availability of medical history (e.g. out-patient medical records or disease histories for hospitalized patients)

Exclusion Criteria:

• Patients participating in clinical studies